We have a comprehensive intellectual property portfolio for imaging and treatment of solid tumors to improve patient outcomes.
We have completed a First-in-Human (FIH) trial using our antibody, called Miltuximab®.
We have completed a first in human trial using our antibody, called Miltuximab
developing solid tumor therapeutics.
Miltuximab® for Therapeutic & Imaging Applications.
Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, glioblastoma, esophageal and ovarian cancers.
We are examining multiple mechanisms of action including:
– Bispecific antibodies
– Immune cell engagement and activation
We have now completed a First-in-Human trial in Australia using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).
The trial dosed 12 patients and no drug-related adverse events were observed.
Glytuzumab® refers to the humanized version of Miltuximab® and also targets human GPC-1. The Glytuzumab® program is currently undergoing Lead Optimization and Lead Selection. Several humanized leads have been generated with similar binding affinities to that of the parent molecule Miltuximab®. The final Glytuzumab® lead selected will be taken forward from cell line development through to large scale GMP production for future clinical trials.
GlyTherix’s Miltuximab® antibody becomes the flagship project for Co-operative Research Centre Project Grant
Preclinical work now completed for upcoming Phase I clinical trial in GPC-1 expressing solid tumours. This will use Miltuximab® labelled with either 89Zirconium for imaging or 177Lutetium for therapy
First-in-Human clinical trial of Miltuximab® labelled with 67Gallium for imaging met primary endpoint of safety in all 12 patients
Antibody composition of matter patents granted EU and US
Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers
The second stage of pioneering MILGa clinical trial of Miltuximab®
Commenced First-In-Human trial of Miltuximab®
2015 Eureka Prize
Excellence in Interdisciplinary Scientific Research
Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.